MedTrace Logo

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)

NCT00816972 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2022-02-16

No results posted yet for this study

Summary

This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.

Conditions

  • Post-nasal Drip
  • Seasonal Allergic Rhinitis
  • Rhinorrhea

Interventions

DRUG

Desloratadine 2.5 mg

Desloratadine 2.5 mg BID

DRUG

Oxybutynin 2.5 mg

Oxybutynin 2.5 mg BID

DRUG

Placebo for Desloratadine 2.5 mg

Placebo BID

DRUG

Placebo for Oxybutynin 2.5 mg

Placebo BID

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-06-30
Completion
2005-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00816972 on ClinicalTrials.gov